TVA Medical, Inc. today announced the online publication of positive results from the Novel Endovascular Access Trial (NEAT) evaluating its everlinQTM endoAVF System. The 12-month data published online in the American Journal of Kidney Diseases (AJKD), the official journal of the National Kidney Foundation, demonstrate the potential benefit of the novel approach to create hemodialysis access as an alternative to traditional open surgery. (Read More)
BioStable Science & Engineering Announces U.S. Pilot Launch and First Commercial Use of the HAART™ 300 Aortic Annuloplasty Device
-BioStable Science & Engineering, Inc. announced today the first commercial uses of the HAART 300 Aortic Annuloplasty Device in the U.S. by doctors at the West Virginia University (WVU) Heart and Vascular Institute in Morgantown, West Virginia. Drs. Lawrence Wei, Vinay Badhwar and J. Scott Rankin of the WVU Heart and Vascular Institute were the collaborating surgeons for the procedures. The WVU Heart and Vascular Institute is the first of a select group of leading U.S. centers expected to participate in the limited launch of the HAART 300 device this year. (Read more)
Familiar face named CEO of this Nashville startup
Preferral, a Nashville-based startup that aims to simplify physician referrals, has named James Aylward as its new CEO.
Preferral is a web-based application for managing and scheduling patient referrals between doctors. Unlike competitor ZocDoc, which allows patients to schedule appointments with specialists online, Preferral connects physicians offices and is not for individuals. (read more)
UT Medical center offers new technology for parents of babies in their NICU
New CEO for Satchel Health
Telemedicine venture Satchel Health has recruited a former Surgical Development Partners, Symbion and OrthoLink executive to be its new CEO. Founder Ryan Macy has moved into the new role of chief product officer.
Lanson Hyde comes to downtown-based Satchel after more than 12 years at Surgical Development Partners, where he was COO of its hospital division and president of its ambulatory surgery center group. (read more)
New technology lets families see NICU babies from afar
After suffering some complications at birth, Cameron Lambert spent his first two months in the neonatal intensive care unit.
But with six other children, a husband, and a dance studio to run, his mom, Mary Beth, wasn’t able to be with him round the clock. (read more)
Technology at Bryan Health Changes Lives for Local Family with Baby in Neonatal ICU
The Neonatal ICU in Bryan Health has gained a new camera system that is changing the lives of local families.
Kay Clark and her husband Jesse Clark have a daughter who has been in NICU for over 100 days, but are now able to bond with baby through live stream video. Kay says the new technology allows her to spend less time in the hospital. (Read More)
Upstate hospital becomes first in SC to connect parents, babies in ICU through ‘Angel Eye’
Spartanburg Medical Center is the first hospital in South Carolina to use a camera system in its neonatal intensive care unit to allow parents to constantly monitor their babies. (read more)
BioStable Science & Engineering Announces FDA Clearance of the HAART™ 300 Aortic Annuloplasty Device
BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device designed for aortic valve repair. BioStable expects the HAART 300 Aortic Annuloplasty Device to be available to select U.S. heart centers in the summer of 2017. (Read More)
GenomOncology and med fusion announce the addition of PD-L1 Testing and Interpretation to the LungSEQ® and 50SEQ® Plus FISH Tests
med fusion, a Texas Oncology and The US Oncology Network preferred laboratory, and GenomOncology announce the expansion of med fusion’s LungSEQ® and 50SEQ® Plus FISH (for NSCLC) laboratory services to include PD-L1 expression testing. The panels will now help guide treatment selection of immunotherapeutic checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC). Read More
- « Previous Page
- Next Page »